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The ADP,ATP carrier of rat liver mitochondria is specifically inhibited by Meisenheimer-type 
trinitrophenyl (TNP) derivatives of ADP and ATP. Due to a systematic inhibition study we could show 
that the TNP-moiety itself, even in the 2’, 3 ‘-O-cyclic Meisenheimer complex, revealed no inhibition of 
mitochondrial ADP,ATP transport. Nucleosidic TNP-compounds are weak inhibitors. Introduction of a 
phosphate group at the 5’-position, however, enhances the inhibitory power markedly. Our findings point 
to a synergistic effect of the S’-phosphate chain and the TNP-moiety. Irreversible inhibition by TNP- 
nucleotides can be ruled out due to the fact that the inhibited ADP,ATP-transport system is fully 
reactivated by addition of albumin. 
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1. INTRODUCTION 
2,4,6-Trinitrophenyl(TNP)-nucleotides have 
become important tools in the field of 
bioenergetics [l-5], especially in the investigation 
of the mitochondrial ATPase [1,3]. 2’ ,3 I-O- 
(2 fl ,4 n ,6 w -trinitrophenyl)-derivatives of ADP 
(TNP-ADP) and ATP (TNP-ATP) are competitive 
inhibitors in the ATPase reaction catalyzed by the 
isolated enzyme [l] as well as by submitochondrial 
inside-out vesicles [3] due to their high affinity and 
extremely low turnover rate at the catalytic site [ 11. 
TNP-ATP preferentially inhibits the F1-ATPase in 
its non-energized ATP-hydrolyzing conformation 
[3]. However, a structure-inhibitor activity rela- 
tionship of these useful analogs has neither been 
developed nor discussed. 
We have found that the ADP,ATP carrier 
system of rat liver mitochondria is also specifically 
inhibited by TNP-derivatives of ADP and ATP. 
We thus performed a systematic inhibition study 
by employing a variety of TNP-derivatized 
substrate and non-substrate analogs. The 
structure-activity relationship derived is discussed 
in the context of structural data of the TNP-moiety 
obtained by ‘H-NMR spectroscopy and our find- 
ings on bonding interactions of the nucleotide at 
the binding domain. 
Some results have been presented in part as a lec- 
ture [6]. 
2. MATERIALS AND METHODS 
Syntheses of TNP-derivatives of nucleotides, 
nucleosides and ribose-5-phosphate were perform- 
ed with 2,4,6-trinitrobenzenesulfonic acid (TNBS) 
as reactant following [7,8]. After completion of 
the reaction, the solution was evaporated to 
dryness and a mixture of acetone/methanol (3: 1) 
was added. By this treatment, the TNP-nucleotides 
were precipitated, whereas the non- 
phosphorylated TNP-derivatives were dissolved. 
Further purification and characterisation of the 
TNP-compounds was performed as in [8]. The 
TNP-compounds were purified by preparative thin 
layer chromatography on activated silica gel plates 
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(SIL G-200, Macherey and Nagel, FRG) using 
tetrahydrofuran : Hz0 (9 : 1, v/v) as mobile phase. 
Proton NMR spectra were recorded with a Bruker 
WP 250 F8. 
Binding and translocation measurements were 
performed with rat (male Wistar rats Bor : WISW, 
SPF TNO; 150-200 g) liver mitochondria 
prepared as in [9]. Mitochondria (2.5 mg Biuret- 
protein) were incubated at 5OC in a medium con- 
taining 70 mM sucrose, 210 mM mannitol, 1 mM 
triethanolamine, 40 pM P’,P-@s-5 ’ ,5 “-aden- 
osyl)-pentaphosphate (ApsA) and oligomycin 
(4pg/mg protein) (pH 7.2) in 29OF.1 total vol. 
Separation of mitochondria from the incubation 
mixture was done by rapid centrifugation through 
a silicone oil layer (AR 200, Wacker Chemie). Dif- 
ferentiation between carrier-linked (specific) and 
non-carrier-linked (unspecific) binding as well as 
exchange with the endogenous adenine nucleotide 
pool was done as in [lO,ll]. 
3. RESULTS AND DISCUSSION 
At neutral and alkaline conditions typical AB- 
spectra for the H, and fib protons (fig,l) of the 
TNP-moiety were obtained with resonances at v = 
8.21 and 8.26 ppm (pH 7, DzOf, indicating that the 
TNP-derivatives of ribose-containing nucleotides, 
nucleosides and ribose-5-phosphate xist as cyclic 
2’ ,3 ‘-complexes of the Meisenheimer type 
[7,8,12]. By lowering the pH, the Meisenheimer 
complex undergoes a rearrangement to the ether 
form (2’-or-3’) (fig.l), where the H,- and Hb- 
protons are equivalent, as indicated by the respec- 
tive resonance band at 6 = 9.19 ppm (pH 3.5, 
DzS04). This arrangement has pK -5, confirming 
PI. 
The data of table 1 demonstrate that TNP-ADP 
en* /OF 
Fig. 1. 2,4,6-Trinitrophenyl-derivatives of adenosine and 
adenine ribonucleotides. pEGDependency of the 
Meisenheimer complex formation. R = H (adenosine); 
PO3Hz (AMP); P206H3 (ADP); P309H4 (ATP). 
prevents carrier-mediated [‘4C]ADP uptake into 
the mitochondria due to inhibition of carrier- 
specific binding of [14C]ADP (expt.2). The remain- 
ing amount of bound [14C]ADP in the presence of 
TNP-ADP corresponds to that obtained by prein- 
cubation of mitochondria with carboxyatrac- 
tyloside (expt.3). Furthermore, the TNP-ADP 
displaces the same amount of c~rier-bound 
[‘4C]ADP as does carboxyatractyloside (expt.4,5). 
These findings show that TNP-ADP interacts 
specifically with the mitochondrial adenine 
nucleotide carrier protein. The TNP-derivatives 
of AMP, ATP, adenyl-5’-yl-imidodiphosphate 
(AMP-PNP) and CDP exhibit the same properties 
(not shown). The other TNP-compounds in- 
vestigated caused neither a significant inhibition of 
mitochondrial ADP uptake nor a displacement of 
carrier bound ADP. 
Table 2 summarizes &-values for the inhibition 
of ~rrier-mediated uptake of ADP by different 
TNP-compounds. The data show that the starting 
reagent 2,4,6-trinitrobenzenesulfonic a id (TNBS), 
picric acid and TNP-ribose-5-phosphate do not af- 
fect ADP transport at all. Interestingly, the TNP- 
moiety itself, even in the 2’ ,3 ‘-O-cyclic Meisen- 
heimer complex as realized in TNP-ribose-5-phos- 
phate, revealed no inhibition of mitochondrial 
[14C]ADP transport. 
The 2 ’ ,3 ’ -O-cyclic TNP-complexes of 
adenosine (fig.1) and cytidine, however, turned 
out to be weak inhibitors of [14C]ADP uptake. 
This enhancement of the inhibitory potency ob- 
viously is due to the introduction of a heterocycle. 
These results fit earlier findings obtained with a 
variety of base-modified nucleotide analogs. By 
means of these analogs we know that an amidine- 
structured heterocycle [14] must be present in 
order to contact the nucleotide binding domain of 
the protein. 
Introduction of one phosphate group at 
5 ‘-position as in TNP-AMP increases even more 
the inhibitory power. This is in line with our find- 
ing that the cytosolic substrate requires at least one 
negative charge at 5 ’ -position in order to be bound 
by the nucieotide carrier [13,14]. The most potent 
inhibitors are TNP-compounds derived from 
ADP, ATP, AMP-PNP and CDP. The inhibitory 
activity of TNP-CDP points to a synergistic effect 
of the 5 ‘-phosphate chain and the TNP-moiety 
due to the fact that CDP does not bind to the 
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Table 1 
Effect of TNP-ADP on mitochondrial carrier-mediated [14C]ADP transport 
Expt. Sequence of addition [ 14C]ADP 
nmol/mg 
protein 
1 ADP -3os-c 3.52 + 0.13 
2 TNP-ADP - 30 s - ADP -3os-c 0.25 + 0.02 
3 CAT - 30 s - ADP -3os-c 0.23 f 0.02 
4 ADP - 30 s - TNP-ADP -3os-c 1.73 * 0.10 
5 ADP - 30 s - CAT -3os-c 1.60 -+ 0.08 
Incubation of mitochondria was done as in section 2 and terminated (C) by 
centrifugation: [‘4C]ADP, 60 pM; carboxyatractyloside (CAT), 250 FM; TNP- 
ADP, 250 pM. The differences yield from: expt.1 and 5, 1 and 4, inhibitor- 
sensitive (carrier-specific) binding of [14C]ADP; expt.5 and 3, 4 and 2, carrier- 
mediated uptake; expt.2 and 3, inhibitor-insensitive (carrier-unspecific) binding. 
Data represent mean + SE for 4 separate determinations; range of confidence 
is 95% 
Table 2 
Mitochondrial carrier-mediated [14C]ADP uptake 
(Iso-values of TNP-derivatized compounds) 
Compound 40 bM1 
TNBS >l.O 
Picric acid >I.0 
TNP-ribose-5-phosphate -1.0 
TNP-adenosine 92 
TNP-cytidine 124 
TNP-AMP 35 
TNP-ADP 18 
TNP-ATP 30 
TNP-AMP-PNP 43 
TNP-CDP 50 
Incubation sequence: Inhibitor - 1 min - [14C]ADP 
(60pM) - 10 s - carboxyatractyloside (500 PM) - 
30 s - centrifugation. For further details see section 2 
ADP,ATP-carrier at all [11,15,16]. 
In principle, the mode of inhibition by TNP- 
derivatives could be due to a nucleophilic attack of 
an amino acid residue of the carrier protein at the 
bridging Cl fl -atom of the 2 ’ ,3 ’ -cyclic TNP- 
moiety. This reaction would generate an irreversi- 
ble Meisenheimer type complex between the analog 
and the binding center of the carrier protein. 
8 
Covalent bond formation also could be possible by 
an electrophilic attack of an amino acid side chain 
at the 02 ’ - or 0s ’ -atom of the Meisenheimer com- 
plex; i.e., an electrophilic group mimics a proton- 
like effect (fig. 1) whereby the 2’ ,3 ’ -cyclic TNP- 
complex undergoes a rearrangement to the ether 
form. These modes of irreversible inhibition, 
however, can be ruled out by the results shown in 
table 3. 
The inhibited ADP-transport system is fully 
reactivated by addition of serum albumin. 
Albumin obviously successfully competes for 
TNP-derivatized nucleotides with the carrier pro- 
tein under the conditions employed. Moreover, 
preincubation with albumin prevents the inhibition 
exerted by TNP-compounds. A similar effect was 
demonstrated for TNP-ADP and TNP-ATP in- 
duced inhibition of MFi-ATPase [3] and azo-dye 
mediated inhibition of the ADP,ATP carrier [17]. 
Taking into account that 2’,3’-cyclic TNP- 
adenine nucleotides are strong, active site-directed 
inhibitors with respect to the ADP,ATP carrier, 
new aspects are provided to the mode of inhibition 
of 2’ - and/or 3 ’ -acyl-, aryl-, alkyl- and alkylidene 
derivatives of ADP. 2 ’ ,3 ‘-Cyclic ADP analogs as 
2’ ,3 ’ -O-methoxy-methylidene- and 2’ ,3’-o- 
isopropylidene-ADP do not show any displace- 
ment of carrier-bound ADP [ 181. 3 ’ -0-alkyl-ADP 
analogs exhibit weak carrier-specific binding [ 181 
whereas 3’-O-esters of ADP [ 19-221 (e.g., 
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Table 3 
Prevention and abolition of inhibition 
Expt. Sequence of addition [ 14C]ADP 
nmol/mg 
protein 
1 CAT - 1 min - ADP - 30 s C 0.23 ? 0.02 
2 ADP - 10 s - CAT - 30 s - C 1.01 * 0.08 
3 TNP-ADP - 1 min - ADP - 30 s C 0.26 + 0.02 
4 Albumin - 1 min - TNP-ADP - 1 min - ADP - 10 s - CAT - 30 s - C 0.91 + 0.07 
5 TNP-ADP - 1 min - Albumin - 1 min - ADP - 10 s - CAT - 30 s - C 0.96 + 0.08 
Incubation of mitochondria was done as in section 2 and terminated (C) by centrifugation: [14C]ADP, 60~M; 
carboxyatractyloside (CAT), 250 ,uM; TNP-ADP, 250 pM; bovine serum albumin, 2.5 mg. Data represent mean + SE 
for 4 separate determinations; range of confidence is 95% 
3 ' -arylazido-derivatives [20], 3 ' -0-[5-(dimethyl- 
amino)-naphthoyl-l]-ADP [21] and 3’-o- 
(naphthoyl-1)-ADP [21]) interact strongly with the 
ADP,ATP-transport system. 
The different binding properties of 3 ’ -O-alkyl- 
compared to 3 ’ -0-acyl-ADP analogs provide 
evidence that a 2 ’ = 3 ' -0-acyl transfer reaction 
[23,24] is involved in the inhibition. The inhibitory 
action is assumed to depend on a 2’,3’-O-alkyl- 
hydroxy-methylidene transition-state intermediate 
which is stabilized by protein interaction. Such a 
2’,3’-O-cyclic system is present in TNP- 
compounds. 
This point of view is furthermore substantiated 
by the fact that 3 ’ -tosyl-2’ -dADP which cannot 
undergo the aforementioned cyclisation due to the 
lack of the 2’OH-group, is a lo-fold poorer in- 
hibitor [6]. 
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